Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities

Chimeric anti-podoplanin mAbs produced by CasMab technology possess high antitumor activity via ADCC and CDC activities

An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2016-12, Vol.69, p.S57-S57
Hauptverfasser: Kunita, A, Kaneko, M.K, Ogasawara, S, Fukayama, M, Kato, Y
Format: Artikel
Sprache:eng
Schlagworte:
Anticancer properties
Antitumor activity
Cancer
Cytotoxicity
Glioblastoma
Glycoproteins
Hematology, Oncology and Palliative Medicine
Lung cancer
Mesothelioma
Monoclonal antibodies
Technology
Toxicity
Tumor cell lines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An abstract of the study by Kunita et al developing novel mouse anti-PDPN mAbs, LpMab-2, LpMab-7, and LpMab-23 using the cancer-specific mAb (CasMab) technology is presented. In the study, mouse-human chimeric anti-PDPN mAbs, chLpMab-2, chLpMab-7, and chLpMab-23 were generated and characterized. They investigated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities of chimeric anti-PDPN mAbs in vitro. Results, novel chimeric anti-PDPN mAbs showed ADCC and CDC activities against CHO/hPDPN, glioblastoma, mesothelioma, or lung cancer cell lines.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)32757-5